Last reviewed · How we verify
Amphinex, Gemcitabine and Cisplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Amphinex, Gemcitabine and Cisplatin (Amphinex, Gemcitabine and Cisplatin) — PCI Biotech AS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amphinex, Gemcitabine and Cisplatin TARGET | Amphinex, Gemcitabine and Cisplatin | PCI Biotech AS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amphinex, Gemcitabine and Cisplatin CI watch — RSS
- Amphinex, Gemcitabine and Cisplatin CI watch — Atom
- Amphinex, Gemcitabine and Cisplatin CI watch — JSON
- Amphinex, Gemcitabine and Cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). Amphinex, Gemcitabine and Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/amphinex-gemcitabine-and-cisplatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab